Latest / The MaineHealth Podcast / MaineHealth’s Precision Medicine Pilot - AOD 02-04-26
Transcript
- 0:00Hey, good day, care team. It's great to be with you. And, you know,
- 0:03one of the questions I've been getting a little bit lately is,
- 0:06hey, what's going on with York Hospital and what's the progress there?
- 0:09And we're still making really good progress. So we've finished most of our due diligence.
- 0:14We've sort of come to terms on what it would look like if they joined MaineHealth.
- 0:18And no real surprise there would look like pretty much all the other hospitals
- 0:21who've become in health communities that have become part of MaineHealth historically in the past.
- 0:26Still have ways to go with regulatory approval. We have a Certificate of Need
- 0:30hearing next week, which we think will be an important milestone.
- 0:34And then, of course, ultimately, we need an opinion from the Antitrust Department
- 0:38of the Attorney General's Office in the state of Maine to make sure there's
- 0:41no antitrust issues there.
- 0:43And hopefully things continue to progress.
- 0:45And, you know, sometime this year, we would love to see York Hospital part of
- 0:49the MaineHealth family.
- 0:51So I had the opportunity to spend time
- 0:54with their board yesterday and just wanted to try to give them a sense of who
- 0:59we are and what we're trying to become moving forward into the future and talked
- 1:02with them about really four big forces that are already starting to act upon
- 1:08us and are going to continue to act upon us over the next foreseeable future of many years.
- 1:14And these are four really big forces that, frankly, no matter what we do,
- 1:19there's just not a rock big enough for us to hide under to escape them.
- 1:24They're going to impact us pretty significantly.
- 1:26The first is the fact that there are going to be significant federal budget
- 1:31constraints for the foreseeable future.
- 1:33And so that's going to put a lot of pressure on us financially as the federal
- 1:37government struggles with its own financial challenges.
- 1:40That means that state budgets are going to struggle as a result of that,
- 1:44not just with health care, but with lots of things that They're going to continue
- 1:47to put pressure on health care funding for Medicare, for Medicaid.
- 1:52And some of you who may have read the business section of the newspaper last
- 1:55week, even Medicare Advantage insurance companies are bracing for what may be
- 1:59very difficult 2027 for them based on insurance.
- 2:02You know, some comments by federal officials on funding for Medicare Advantage.
- 2:07So that's going to be a big challenge for all of us that we'll have to continue
- 2:10to work through and navigate through.
- 2:13The second one is the significant shift in demographics that's really happening
- 2:18not only across the country, but really every continent in the world except for Africa.
- 2:24Where we're going to see both population decline moving forward,
- 2:27but also significantly aging population.
- 2:29And so the next nine years, it's estimated that in 2035, we'll see nearly 100
- 2:35million adults over the age of 65, roughly 85 million children in this country.
- 2:41So for the first time, we'll have more adults over the age of 65 than kids.
- 2:45And about 185 or so million working-age adults.
- 2:48So when Medicare was created, there were seven and a half working adults for
- 2:52every Medicare beneficiary. There's going to be less than two to one in nine
- 2:56years, which is, again, going to compound some of the financial pressure that we're going to feel.
- 3:01But as we age, we require more health care services, and so we're going to feel
- 3:04a significant demand for that care.
- 3:06But the pool of working-age adults is going to shrink on a relative basis,
- 3:11which means that we're going to still struggle with the workforce challenges
- 3:13that we're feeling today unless we come up with ways to solve some of those challenges.
- 3:18One of the ways we may augment our workforce is through the use of artificial
- 3:21intelligence, and that's the third big force that's going to continue to act upon us.
- 3:25It's here today and will continue to be for the future.
- 3:29Some may have seen that in the state of Utah, they have given legal authority
- 3:33for an AI program to actually prescribe medications without a human in the loop.
- 3:39For patients who are on chronic conditions who've seen a doctor and met certain criteria.
- 3:43The artificial intelligence is able to actually write a prescription for those
- 3:46patients. So we're going to continue to see pretty significant advancement,
- 3:49in some cases disruption, around healthcare through the use of artificial intelligence.
- 3:54And that leads us to our fourth one, which is precision medicine.
- 3:59We're going to see some rapid advances in biomarkers and genomics.
- 4:05In fact, we're starting to see some really interesting biomarkers becoming available.
- 4:10There was a test recently that seems fairly robust that is able to capably predict
- 4:16which women, for example, will experience postpartum depression,
- 4:20even, you know, at the early stages of their pregnancy.
- 4:22And so it could help prepare them for what that experience would be like and
- 4:26help promote a better outcome.
- 4:28And we're going to see continued development on tests for Alzheimer's and other
- 4:32conditions that plague us.
- 4:33And then we're already seeing significant improvement in the ability to treat
- 4:37really difficult conditions. For example, sickle cell in some cases can now be cured...
- 4:42Which is really remarkable and revolutionary. But that, too,
- 4:46is going to put a lot of strength on us. It's going to change the way we think about delivering care.
- 4:50And to help us understand that today, we've got the chair of the Department
- 4:54of Medicine from Maine Health, Maine Medical Center, Dr.
- 4:57Aji Djamali, who's really helping lead our internal efforts around precision
- 5:02medicine, who's going to talk about that today.
- 5:04So we're really excited to have Dr.
- 5:07Djamali on the program and hear his thoughts on this. So with that,
- 5:12we'll pull in Caroline to kick us off today.
- 5:15Good morning, Andy. Good morning, everybody. As always, if you've got questions
- 5:20for Dr. Djamali or for Andy, we've got the chat available.
- 5:23Please use your first and last names and pronouns.
- 5:26I'll only use your first name on the program. And if you don't even want that, just let me know.
- 5:30I know some people have very recognizable first names and they prefer they not get used on the program.
- 5:35We also have a number of questions that have come in over email from our Ask
- 5:40Andy inbox. And so we'll be getting to those as well on some of the other topics
- 5:44that are on your mind right now.
- 5:45But for now, I think, Andy, we got a lot to talk about with Aji, so we should get to it.
- 5:50Andy, welcome. Thank you for being here with us today. Thank you for having
- 5:53me. Yeah. So, Aji, it seems like you really kind of flew in here,
- 5:58And have really hit the ground running, both in terms of how you've really helped
- 6:03us think about clinical care delivery, but just your leadership in general.
- 6:07And it's been really kind of fun and interesting to see just how quickly you've
- 6:11arrived to create impact.
- 6:14But I keep thinking like you've only been here six months, but it's been longer
- 6:17than that. So when did you come to Maine Health?
- 6:20Thank you, Andy. I joined Maine Health four years ago.
- 6:23Four years ago. It blows my mind. It just doesn't seem like it's been that long.
- 6:26And talk a little bit about what you were doing before you came here to MaineHealth. Sure, absolutely.
- 6:33Thank you again for having me. I joined MaineHealth from University of Wisconsin-Madison,
- 6:39where I served as a transplant nephrologist, clinician investigator,
- 6:44and Division Chief of Nephrology.
- 6:47Overall, I was in Wisconsin for 24 years.
- 6:52And after considering that timeframe and the fact that our children left home
- 6:59to go to college, we were looking for another opportunity for growth. And...
- 7:07We joined MaineHealth. It has been a tremendous experience.
- 7:11I will share with you, you were saying that things were going well,
- 7:15but really I have felt extremely well accompanied with a group of people that
- 7:22have been wonderful leaders and supporters of our mission, vision, and values.
- 7:28Yeah, outstanding. And what were some of the things that made you think that
- 7:32MaineHealth might be the right
- 7:33fit for you? I would say the first thing is really for me, the culture.
- 7:38And then talking about the culture, having lived in Wisconsin for 24 years,
- 7:45the Midwest culture really resonates with me.
- 7:47And I felt that those values were really also present here.
- 7:52And then it's a work environment that not only amplifies those values,
- 8:00but also my leaders that valued me and made me feel valuable.
- 8:06And the people I work with in the Department of Medicine, which is one of the largest departments,
- 8:12and those division chiefs and vice chairs and clinicians and administrative
- 8:18staff people have been wonderful people to work with.
- 8:23So that's how I have felt really valued and valuable over the past four years,
- 8:27and I hope to stay here for a while.
- 8:30Yeah, and like many of our care team members, Adji, your role really sits at
- 8:34the intersection of clinical care delivery,
- 8:37academics, and research, which is really good because precision medicine really
- 8:42is already and is going to continue to touch all three components of our main health mission.
- 8:49So, Adji, I have to ask, what is precision medicine? How do you define that?
- 8:54That's a great question.
- 8:55There are many definitions, but one definition that I think of frequently is
- 9:00precision medicine is when we use a person's genetic makeup.
- 9:07Their environment, their clinical history, and also their lifestyle to predict,
- 9:16prevent, and treat diseases.
- 9:20So in other words, it's individualized care compared to the traditional medicine
- 9:26that we grew up with, that is, what works for most people.
- 9:31So here we are thinking about what works specifically for this person.
- 9:38Okay, which is a little bit different than what we've done historically.
- 9:42In some cases, historically, we've gotten population-based data through clinical
- 9:46trials and other things.
- 9:48And then try to treat patients to see if it works or not.
- 9:53But this gives us a little more certainty about how that looks, doesn't it?
- 9:58Absolutely. It is about personalized care. and something that's,
- 10:04We need really to start integrating in our clinical practice.
- 10:08It is going above and beyond research.
- 10:12It has to become part of our DNA and culture.
- 10:17No pun intended. No pun intended. To help with the health of our communities. Yeah, for sure.
- 10:25And so to that point, Aji, is this something that only wealthy people will be
- 10:31able to participate in or afford? or is this something that's going to touch
- 10:34everyone in the community? That's a great question.
- 10:36We are definitely working together so that it helps every single person in our
- 10:43community and not only those that have the means.
- 10:47And I have to give kudos to yourself and to Adrian Moran for the vision to implement
- 10:54this as part of our vision for the future.
- 10:57Well, let's talk a little bit about that vision. So what exactly does this program
- 11:01or does this type of care delivery look like at MaineHealth in the future?
- 11:06Sure. Thank you. We are thinking that in 10 years, we would like to have a state-of-the-art,
- 11:14fully integrated precision medicine program at MaineHealth, where we integrate not only genomics,
- 11:21but also proto-mix,
- 11:24other biomarkers, as you were mentioning earlier, transcriptomics.
- 11:27And especially artificial intelligence to deliver the care that every single
- 11:33person in our community deserves at an individualized level.
- 11:36As you can see on this slide, we have devised a phased approach to get to that
- 11:44point. and what you'd like to do is to start with a pilot.
- 11:49Clinical implementation phase where we are going to reach out to patients from
- 11:55our primary care communities, as you were mentioning a bit earlier,
- 12:00and invite them to participate in this clinical phase.
- 12:04We are hoping to have about 5,000 patients to whom we will offer genetic screening,
- 12:13testing for the most common conditions that are hereditary, including cancers,
- 12:21cardiovascular conditions, metabolic diseases.
- 12:25And once we have that clinical implementation pilot phase ironed out,
- 12:30then we will expand this further to specialty care and include all other medical
- 12:38specialties that have already been doing some of this or have not yet integrated
- 12:43it fully in their clinical practice.
- 12:46The next phase would be to expand this for our academic mission to support research
- 12:53and clinical investigation with the NIH,
- 12:58pharmaceutical industry, and
- 13:00other foundations to support and advance the field. and advance the field.
- 13:06And then finally, hopefully, in maybe less than 10 years, we'll have that fully integrated program.
- 13:11Yeah, so why start with primary care? That's a great question because we feel that.
- 13:20We have to change the culture. This is a change management approach that we want to implement.
- 13:29And our vision that is working together, so our communities are the healthiest in America.
- 13:35We have to really start at the base of the pyramid instead of pushing it top down.
- 13:42So we want our primary care physicians and staff and learners to feel comfortable
- 13:47with this. Because in 10 years, this is going to be standard practice.
- 13:51And we want our patients from the community to feel comfortable with this approach
- 13:56as well, so that as their children grow and as their families grow,
- 14:01we can offer these practices to them.
- 14:04And there's no other way, really, we feel collectively to address this in a
- 14:11comprehensive fashion other than reaching out to our communities from primary care.
- 14:16Okay, so interesting. So you said in 10 years, this will sort of be the way
- 14:21we practice medicine and sort of mainstream.
- 14:23Is that really true? This is not just something on the fringe that we're trying
- 14:27to do? We're trying to make a name for ourselves or get kind of cute with something here?
- 14:31No, I don't think so. I think that if we didn't start now in 10 years,
- 14:36we will sourly regret it.
- 14:38Our communities will be upset with us why we don't have a precision medicine
- 14:42program that's fully integrated and part of standard of care.
- 14:46Yeah so this is this is going to come pretty fast i think
- 14:49and i think jean you would know
- 14:51better than me but i think artificial intelligence will be a tool that's used
- 14:55to really accelerate the progress of this exactly and i think probably like
- 15:01you i worry a bit that there are going to continue to be genetic tests that
- 15:06become increasingly available on the commercial market many patients will start to.
- 15:11Sign up for directly. I think there'll be a lot of direct to consumer marketing.
- 15:14And I worry that if we're not getting ahead of this, that it's going to be hard
- 15:18to advise those patients both
- 15:20on the front end around, is the test really worthwhile or makes sense?
- 15:24But also on the back end, when they show up with a positive test result to one
- 15:27of our primary care teams and the physician or APP is now confronted with what
- 15:33does this mean and what do we do next with this? Does that make sense to you?
- 15:38Absolutely. That's exactly the engine behind.
- 15:41Yeah. So this is going to happen, I think, in a pretty brisk clip.
- 15:45And again, we're already seeing some remarkable treatments become available.
- 15:51And we recently had a patient here, a pediatric patient at MaineHealth,
- 15:56Maine Medical Center, Portland campus, a newborn that had a really severe genetic
- 16:01condition that would ordinarily confine that infant to a very short life that
- 16:07would involve a lot of medical care.
- 16:09It would be very uncomfortable and effectively was cured through genetic engineering
- 16:15using a CRISPR vector that fixed a genetic mutation.
- 16:21So that child, we anticipate, is probably going to have a fairly normal life.
- 16:24And that's really miraculous and something I don't think we would have thought of 10, 15 years ago.
- 16:30Now, the treatment for that child cost $2.2 million.
- 16:37So, what do you think some of the economic and healthcare economic impacts of
- 16:41some of this care and treatment might be?
- 16:44That's another great question. I think this is going to be expensive.
- 16:47There's no doubt about this. And it's...
- 16:51Should not be a reason for us not to pursue the path, as we were mentioning
- 16:56before, because our commitment is up to our communities, first of all.
- 17:00And it is up to us to find the best means to fund these projects and these approaches for our patients.
- 17:08So, yeah, it's not going to be inexpensive, but we are hoping that with artificial
- 17:13intelligence, for example, and the new tools that it brings with it,
- 17:19we can reduce some of those costs. Yeah, interesting.
- 17:23So, Aji, we've talked about precision medicine and genetic testing around really
- 17:29precisely treating a patient and identifying the right way to affect an outcome
- 17:36that's in the best interest of the patient.
- 17:38Does that mean that we may actually be able to sort of tailor things like which
- 17:42drug to use if there are multiple drugs?
- 17:44So, for example, if a patient has high cholesterol, has risk factors for heart
- 17:48disease, you could actually identify which cholesterol medication would give
- 17:52that patient the best outcome. That's absolutely correct. Yes.
- 17:55In the gene list that we are proposing to start with, to study as a screening tool,
- 18:05we have a list of about 12 most common pharmacogenes.
- 18:10And these are genes that are primarily affecting the metabolism of drugs.
- 18:16These are enzymes that are in the liver, and some mutations that are found commonly
- 18:23can make those enzymes hyperactive or hypoactive,
- 18:28which means that a drug can be metabolized too fast or not metabolized enough.
- 18:35To your point, if some people have a mutation for one of those enzymes,
- 18:40that would make them totally resistant to a specific cholesterol drug.
- 18:46Or somebody, let's say, has a heart attack, and we know they have to go on a blood thinner.
- 18:51But there are common mutations that make people resistant to some of these blood thinners.
- 18:56And our hope is that we will identify these mutations early and implement the
- 19:01right drugs for the right patient in the right condition. Yeah, absolutely.
- 19:05So one question I have, Aji, is in talking about this around how to tailor
- 19:10care for the individual,
- 19:12Is there ever a chance that this could play a role in thinking about public
- 19:15health around sort of the amount of genetic disease that we see in a broader community? I think so.
- 19:24Each state has its own phenotype of people through hundreds of years of immigration,
- 19:32and identifying common gene mutations will help us improve overall population
- 19:40health, And that would be more applicable,
- 19:43for example, in Maine than in Wisconsin or in Texas.
- 19:48Definitely, yes. Yeah, because I think we even know today with good intent by
- 19:53everybody that when we look at the amount of some of the genetic conditions
- 19:57that we treat, we know we're missing some that are in the community today.
- 20:00And some of those can be impactful. Again, sort of thinking about like familial
- 20:06hypercholesterolemia or Lynch syndrome where patients may be at higher risk
- 20:09for cancer in the future,
- 20:10but don't necessarily know that earlier in their life unless they have genetic testing. Absolutely.
- 20:16This to a point that the CDC has identified a list of 10 genes that they call CDC Tier 1.
- 20:23These 10 genes are primarily involved with hereditary breast and ovarian cancer.
- 20:30With hereditary non-polyposis colon and rectal cancer and with familial hypercholesterolemia
- 20:37that you were mentioning.
- 20:38The reason the CDC has defined these 10 genes as top tier is because they are very prevalent.
- 20:45And there are actionable interventions that can be implemented.
- 20:49It's not always medicine.
- 20:52Sometimes it's screening, for example. If one of those mutations is found for
- 20:57breast and ovarian cancer, then
- 20:59we can accelerate the screening with mammograms, with MRIs, for example.
- 21:05If there is a Lynch syndrome mutation that's found, then we can accelerate the
- 21:10process of surveillance with colonoscopies that are going to happen instead
- 21:14of every 5 to 10 years, every couple of years that start at an earlier age.
- 21:19And furthermore, and probably more importantly, is that once we find these mutations,
- 21:24then we can offer to that person what we call cascade testing.
- 21:30And cascade testing helps with testing or screening of family members of these patients themselves.
- 21:38Have not been affected by the condition yet, and we want to support them early on.
- 21:44Okay, yeah, that's helpful. And I think in some ways you may have answered my
- 21:48next question, which is, can you talk to us a little bit about what the patient journey looks like?
- 21:53So if I'm a patient, what should I sort of expect in the future as we begin
- 21:57thinking about offering more of this type of care?
- 22:01Sure. So for our first phase or phase one,
- 22:04that's the pilot clinical implementation phase, Our primary care practices,
- 22:09we have identified eight primary care practices in the southern region as well
- 22:15as in New Hampshire that have about 60,000 patients.
- 22:20We are going to send an invitation to all these 60,000 patients through MyChart
- 22:25to invite them to participate in this clinical implementation pilot approach.
- 22:31And if they consent that, this is going to be a digital consenting process.
- 22:35We'll have enough online information for them, and we will have a genetic counselor
- 22:39available for questions, and of course, I'm personally always available as well.
- 22:45And then, let's say they consent to the testing or the screening.
- 22:51At that point, we will send them a kit.
- 22:54To home. It's a simple buckle swab or cheek swab.
- 22:59There's a cotton they put in
- 23:00their mouth and they put it back in the tube and then they send it to us.
- 23:04Then we will do the testing and once the testing is done, the results come back.
- 23:09We will look at it in a conference, in a care review board fashion with a multidisciplinary approach.
- 23:20We'll have a geneticist, we'll have clinicians, we will have researchers, et cetera.
- 23:25So we all are going to review that result on a weekly basis and then inform
- 23:29the primary care physician and the genetic counselor to reach out to the patient
- 23:34and help them understand the results of this test.
- 23:39And then downstream, if there's an intervention that needs to be implemented, we will support that.
- 23:45So a question for you. So part of this pilot program, If I'm a parent and want
- 23:49my child tested, is that possible?
- 23:52Absolutely, yes. If your child is a minor, you can consent for your child and then yes.
- 23:59So talk a little bit about how the advancement of precision medicine and how
- 24:04we're thinking about that here at MaineHealth will impact research.
- 24:09That's another great question. We have been collaborating with researchers from
- 24:15the MaineHealth Institute of Research, or MHIR.
- 24:18They have been true partners in the design of this pilot phase,
- 24:23and they will remain partners throughout.
- 24:26Our hope is that we will create two sets of databases or registries.
- 24:34One is for the clinical information and the genetic information,
- 24:38and one is a biorepository for potential samples that patients may have throughout. Now.
- 24:47The consenting process will be a tiered consenting process.
- 24:51Patients do not have to consent to participate in any of the research pieces
- 24:55of this approach, but they may.
- 24:57And if they did, our researchers are going to drive hypothesis-driven research
- 25:03proposals that will advance the field further. Okay.
- 25:07So how is this going to impact medical education when we think about residents,
- 25:13physicians, APPs, nurses, other clinical individuals?
- 25:17Yeah, that's part of the change management, and we want to support these target audiences.
- 25:27Currently, our medical students are the most advanced in genetic disease understanding
- 25:32compared to the rest of us.
- 25:34So we have created an education work group that includes those target audiences
- 25:41from residents to clinical research coordinators,
- 25:46geneticists and genetic counselors and clinicians and staff members from those clinics.
- 25:51They actually are super excited to help us with this, and they want to make
- 25:57sure that we develop education materials that are usable and targeted for each of these groups,
- 26:04including our patients, obviously, so that we can advocate for it and develop the project further.
- 26:11Yeah, really interesting. So, Aji, thank you for getting us up to date on all
- 26:17of this. I think we're going to be hearing more and more about this. on a regular basis.
- 26:22So one final question for you.
- 26:24So if I decide that I want to have genetic testing and I have that done when
- 26:30I'm 20 years old, do I then need to go back and have it repeated every five
- 26:34years or every two years or every 10 years?
- 26:37That's a great question. We are hoping not because the approach that we are
- 26:42offering is a whole genome sequencing.
- 26:46And we will keep that information in a bank and offer specific testing on those
- 26:56top 100 genes that I was just talking about earlier as first phase.
- 27:02Because we have currently interventions for these 100 genes.
- 27:07But what if in 10 years we had new genes identified that we had interventions,
- 27:13we have developed interventions for? then we don't need to redo the testing that is in.
- 27:20Biobank, and we can query that and test for that mutation.
- 27:25Yeah, because your genetic, your DNA is not really changing over time.
- 27:29And so the idea would be that you would test once, you would sequence the whole
- 27:32genome once, and then have the opportunity to query it multiple times in the future.
- 27:38Okay, well, good. We should probably bring Caroline back in.
- 27:40I bet there's some questions out there, but people have stimulated some interest here.
- 27:44And Caroline, I think we should disclose, too, that normally we have a production
- 27:47meeting when we get together and the guest gets to hear some of the questions
- 27:51we're going to ask and all of that stuff. And we weren't able to do that because
- 27:54of conflicting schedules.
- 27:55And so this was all cold on Aji. He didn't know what I was going to ask this morning.
- 27:59And I think he did a remarkable job. He had some idea, but definitely not the
- 28:04full breadth of it. So yes, you've done a great job.
- 28:07And now you get to get the questions from the care team, which you definitely
- 28:11don't know what's coming. So we have a couple already.
- 28:14First one is from Anne. Anne wanted to know, what the plan is to increase genetic
- 28:19counselors if we're taking this precision medicine approach with genetics?
- 28:24Thank you for that question. And definitely without genetic counselors,
- 28:28we would not be able to develop this program.
- 28:32And we have prepared a pro forma
- 28:37that includes three genetic counselors to participate in this project.
- 28:43And I am delighted to share that The preliminary budget for the early phase
- 28:48was approved and we are going to soon post for the recruitment of a genetic
- 28:54counselor to join the team for this precision medicine project.
- 29:00We also have a question from Suzanne, and Suzanne wanted to know what,
- 29:04if anything, we're doing to assist patients in the genetic testing pilot with
- 29:08that financial impact of the testing, since the tests are really expensive, as we talked about,
- 29:13and a lot of payers require supporting evidence of potential illness to cover them.
- 29:18Thank you, Suzanne. That's another good question. For the pilot phase,
- 29:23the health system is going to cover all the costs of genetic testing,
- 29:29And we are working with our
- 29:32revenue cycle and contracting team to help understand how we can work internally
- 29:39to also cover the cost of downstream interventions that are going to be required
- 29:46if they are not fully covered by the insurance companies.
- 29:51And along those lines, what, if anything, are we doing if, let's say,
- 29:56someone gets their genetic testing done, find out that they have a gene that's
- 30:01likely to maybe to cause cancer in the future, and now the insurance company
- 30:04is like, oh, you are going to be a lot more expensive to insure now.
- 30:08Is there a privacy protection in place so that insurance costs don't get driven
- 30:13up for people who did this testing not knowing what they were going to find? Yes.
- 30:19We are definitely working on that. We have considered the legal implications
- 30:26and the confidentiality components to this.
- 30:32And our ethics committee, Frank Chesa, is involved with this project and is
- 30:40advising us. So we are going to have a good solid plan to offer in the next several months.
- 30:47You okay there, Andy? I'm so sorry. Well, asthma attack. Oh, no
- 30:51Sorry about that, everyone. All right. I'm glad you're all right.
- 30:54Jason had another question for you. Jason wanted to know, how is MaineHealth
- 30:59ensuring advances in precision medicine are accessible and equitable for patients
- 31:04across the whole state, including rural and underserved communities?
- 31:08That's a very good question, Jason. That's our highest priority.
- 31:12For now, we have identified these eight practices that are primary care practices,
- 31:19as I was mentioning, including Norway and the Biddeford campus site.
- 31:24The reason we have selected these is that they are the practices that we believe
- 31:30are the most ready to embrace and implement the operational aspects of this project.
- 31:37But our hope is that in 10 years,
- 31:42we have offered this opportunity to every single patient in the state of Maine
- 31:50and our colleagues in Norway.
- 31:54Yeah, you know, and along those lines, too, one of the big disparities,
- 31:59you know, health equity disparities that we see is around access to clinical
- 32:02trials in rural versus urban environments.
- 32:06And so we think that there may be some ability to use this program as a way
- 32:10to work on trying to overcome that.
- 32:12And I know our research institute is very committed to trying to solve that problem.
- 32:16We think we're a great state and in, you know, in New Hampshire as well to help figure that out.
- 32:22We have two kind of related questions that is both related to this topic and
- 32:28to another hot topic that's been coming in.
- 32:30So I'm going to give you the first question, Andy, about ICE because it also
- 32:35relates to a question about precision medicine that we just got.
- 32:38And you'll understand when I ask them both.
- 32:39The first question that came from Courtney was, Courtney wanted to know what
- 32:44tangible plans MaineHealth had to support the immigrant community amid the ICE
- 32:50raids that were going on the past couple weeks.
- 32:53Those have now subsided, it sounds like.
- 32:56Specifically, she wanted to know about MaineHealth partnering with Palantir
- 33:01AI technologies because ICE also has partnered with Palantir.
- 33:06So she wanted to know what steps we were taking to make sure immigrant patients
- 33:10and employees' information or anyone who comes to MaineHealth is not being given
- 33:15to ICE to conduct arrests.
- 33:18So could you address that? Yes, I certainly can. And so, certainly with the
- 33:23contractual obligations Palantir has with us, the information that we share
- 33:28with them on our revenue cycle pilot is really limited to just that.
- 33:32It's not to be used for anything else outside of that.
- 33:35And Palantir has to follow the law with respect to protected health information,
- 33:39just like we do or any other organization does.
- 33:42Having said that, we are having conversations to validate that with Palantir
- 33:47and ensure that we're satisfied with the response around that.
- 33:51And it certainly is complicated when it comes to things like Palantir and using
- 33:56them in this circumstance.
- 33:58We recognize that many are not happy about the fact that they're also doing
- 34:02this with the federal government with respect to.
- 34:05Helping analyze data for ICE. And it becomes really complicated because the
- 34:09reality is, if we choose not to use Palantir, the data that Palantir is storing
- 34:16with ICE is being stored on Amazon Web Service servers.
- 34:19And so I don't know if that means that none of us should use Amazon or not use
- 34:24Amazon Prime or any other Amazon product or cancel our Prime subscriptions.
- 34:30I'm not sure. Or they, you know, ICE uses Microsoft for many of their sort of
- 34:37business functions from that standpoint. We use Microsoft.
- 34:40And so if we decide we don't want to use Microsoft for that reason,
- 34:43then I guess we could go to Google and become a Google organization.
- 34:46Except that Google has a really big ICE contract as well.
- 34:51Even when it comes to genetic testing, we do genetic testing on Thermo Fisher
- 34:56Scientific instruments.
- 34:58And Thermo Fisher Scientific has a contract with ICE. And so it becomes really
- 35:02difficult to think about how we manage all of these relationships when the reality
- 35:06is it's going to be hard to withdraw that.
- 35:08Now, at the same time, we definitely want to make sure the data is protected. It's a real concern.
- 35:14And not just for use with immigration and customs enforcement,
- 35:20but also for any other use, too, where it shouldn't be used.
- 35:23So that's something we're going to want to continue to make sure with all of
- 35:26our vendors that we have really good assurances and certainty that the data
- 35:30is being used exactly what they're describing they're going to use it for,
- 35:33which is really to help support us in the care of our patients.
- 35:37So the related question that came in in the chat was, given that Palantir is
- 35:42helping with our billing department and working some of these claim appeals
- 35:45that might come up, is there any notice being sent to patients regarding the partnership?
- 35:52Is there an option for patients to opt out of having their information shared with Palantir?
- 35:57Not necessarily at this time. And I think, again, it would be difficult to manage
- 36:00all of that realistically on a consent-by-consent basis. And I guess we would
- 36:05have to do the same thing around the use of all these other tools that the federal
- 36:09government is contracted with.
- 36:11And ultimately, it's a contract with the federal government.
- 36:13It's a department of the federal government. But, you know, we contract with
- 36:16the federal government caring for Medicare patients and complying with the rules
- 36:19around Medicaid patients.
- 36:20And so I think it's a really slippery slope to think about how we would do that.
- 36:24And I realize that Palantir in particular is the one that's gotten a lot of
- 36:28attention on Facegram and Tic Tac and some of these other things.
- 36:31But the reality is there are a lot of companies that are also engaged with ICE
- 36:36and the federal government and a lot of things that people may object to over time.
- 36:39And how we manage that through different administrations, how we manage that
- 36:43through different, you know, control of Congress, how we manage that through
- 36:46all sorts, that's just a really hard thing for us to do. And so I think at the
- 36:49end of the day, we do want to partner with people that share our values and all of those things.
- 36:54We certainly want to partner with people in a way that helps us advance our
- 36:57vision of working together so our communities are the healthiest in America.
- 37:01And at the same time, particularly as we see consolidation of a lot of these
- 37:04companies and other things, it may be hard for us to always escape those companies
- 37:09that choose to do something with some part of the business,
- 37:11whether it's the Department of Defense or ICE or other things that politically
- 37:15we may not always agree with, but they could really help us help our patients.
- 37:19And so that's going to be a conversation that we'll have to continue to engage
- 37:22in and not run from and be realistic about.
- 37:25And we've had a lot of conversations about our partnership with Palantir is
- 37:28the right thing to continue to do. And we'll continue to evaluate that for sure.
- 37:31Ajie, going back to precision medicine, Anne was wondering if there was an age
- 37:36group that you're looking for in terms of the pilot program.
- 37:40That's a very good question and thank you. Yes, we are looking for adults age 21 and older.
- 37:47We are not planning to include pediatrics for the pilot phase.
- 37:56But as we implement this and this becomes part of our standard clinical practice,
- 38:01definitely that will be part of it.
- 38:03Yeah, that was part of what I was trying to get to earlier. I didn't really
- 38:06clarify that for Ajit. He was trying to read my mind.
- 38:08It was too possible. But that was for the pilot program. We're really going
- 38:11to focus on adults and above.
- 38:13And AI obviously is a big part of this. And we did get a couple of questions
- 38:16regarding AI that came in via email.
- 38:19And again, keep bringing those questions in through the chat.
- 38:21That. But Seth wanted to know, Andy, if there was any plan to create a set of
- 38:25ethical guidelines and ethics board or other kind of ethical communication for
- 38:30AI use within MaineHealth.
- 38:31Yeah. So Dan Nigrin, our chief information officer and his team have sort of
- 38:35constructed a framework that helps us evaluate tools and technologies around
- 38:40artificial intelligence to ensure that we're doing things that are safe, reliable,
- 38:44and certainly ethical when it comes to that and the use particularly around patients, for sure.
- 38:49And then another AI question that came in from Michelle regarding AI,
- 38:54she said, we're increasingly seeing new initiatives using AI at MaineHealth.
- 38:58For instance, Ask Clara and Epic, given the significant environmental impact
- 39:03from using AI because of the massive water and energy consumption by data centers,
- 39:08how is MaineHealth reconciling that negative environmental impact with our sustainability initiatives?
- 39:14It's a great question. And the honest answer is, I don't know.
- 39:18And not to say that it's not important, because it is important.
- 39:21There's certainly an environmental impact of the use of artificial intelligence.
- 39:25And not to necessarily say that we shouldn't be responsible in how we think
- 39:29about that. It's also a much bigger problem than I think we can solve at MaineHealth.
- 39:33The reality is that we don't necessarily impact directly the use of energy around those things.
- 39:41That's where we can't account for that outside of main health.
- 39:43It'll be difficult for us to look at how many tokens are generated here and
- 39:46then translate that into wattage and other things to really understand what our use is.
- 39:51Having said that, we still believe we have an obligation to do everything we
- 39:55can to reduce our energy utilization here within the confines of what we can control.
- 39:59Now, having said all of that, the amount of artificial intelligence and inference
- 40:05that's happening right now around the world is enormous.
- 40:08And if we chose to opt out of that, the impact of us opting out of that is not
- 40:14even almost discernible. It's so small.
- 40:16At the same time, if we don't participate, then I think we're going to put ourselves
- 40:20a huge disadvantage in terms of our ability to really impact care in our community,
- 40:25take care of our care team, and help our patients.
- 40:28And so I don't think we have the ability to just opt out of artificial intelligence
- 40:32because of the impact on the environment, although that is real.
- 40:35I think we still have to participate with it and be supportive of efforts to
- 40:39help us think about how we do that responsibly while still thinking about how
- 40:43we can reduce our energy utilization with our continued core operations and
- 40:47our footprint here in Maine, New Hampshire.
- 40:50And I want to give a little shout out to the Andy's Open Door Engage page because
- 40:54you gave a little talk about AI that we posted up there recently.
- 40:59So if you want to see more of Andy's thoughts on use of AI at MaineHealth,
- 41:03I encourage you to look at that.
- 41:05And I think actually that's where a couple of these questions came in because
- 41:07they came in right after that was posted on the Engage site.
- 41:11I want to also turn back to ICE. We got several care team questions in the weeks
- 41:17preceding this program, particularly as ICE ramped up activity. in Maine.
- 41:22Several of them are very similar. So I'm going to try to group them in a couple
- 41:26of places and hopefully people will feel that their questions were answered.
- 41:28But we did get several and the facts on the ground have changed a little bit,
- 41:32but people still have concerns that are really real.
- 41:34So I wanted to put the first one out from Taylor.
- 41:38Taylor had been wondering about what MaineHealth's plan was to protect not
- 41:43only patients, but also staff if ICE were to show up but one of our locations?
- 41:48What is expected of employees if ICE is going to visit the hospital asking questions
- 41:53or starts being aggressive?
- 41:55What if an employee refused to give information to ICE? Would MaineHealth stand behind that person?
- 42:01And in what circumstances would we be able to deny access to ICE without putting jobs in jeopardy?
- 42:10So lots of questions within there, but if you might be able to address that.
- 42:13Yeah, for sure. And I don't know that I'll necessarily hit everything the way
- 42:17it was intended, but we have provided guidance to leaders on how to respond in the event.
- 42:23That ICE shows up at one of our facilities. And certainly that includes who
- 42:28to contact, who to call, and how to approach that.
- 42:31Some of that encourages care team members to reach out to our security forces
- 42:35just because they have the ability and history and experience and knowledge
- 42:39about interacting with other law enforcement officials, which is helpful to us.
- 42:43In terms of expectations, there are a couple that I think are important.
- 42:46First and foremost, we don't want a care team member putting themselves in a
- 42:49position where they would be harmed in any way. So please don't do that.
- 42:52The second thing is, is that we are a law-abiding organization and we expect
- 42:58to follow the rule of law in those circumstances. And that means that we need
- 43:02to protect information as we are supposed to under federal law.
- 43:06It also means that, you know, someone shouldn't be on our property without an
- 43:11appropriate warrant and those types of things.
- 43:13And then at the same time, if someone does have an appropriate warrant,
- 43:16then we need to comply with the instructions of the warrant and follow the directions
- 43:21of law enforcement in those circumstances.
- 43:23So that's sort of how we would want to approach it and hope that it's approached
- 43:27and certainly recognize this creates a lot of anxiety for individuals and the
- 43:32fear that this might happen. And I think we've been fortunate so far that it hasn't to date.
- 43:36But certainly, we've had lots of conversations about this, and we do have material
- 43:41that's available to leaders.
- 43:42It's been distributed, and there are access points for that as well.
- 43:46The other major theme of questions that came in around ICE was really about
- 43:50supporting our care team members, particularly those who may be concerned that
- 43:54they were going to be targeted despite being in the country legally.
- 43:58A number of people were wondering what MaineHealth might be doing to support
- 44:01people who were afraid to come to work.
- 44:03So were there ways that you could donate PTO? Were there ways that their PTO
- 44:08wouldn't be impacted by this?
- 44:10And then the other piece of this is what is being done to emotionally support
- 44:14these care team members?
- 44:16What kind of resources are available to them from MaineHealth to make sure
- 44:20their mental health is being supported during a really stressful time?
- 44:23So would you be able to address those issues as well? Some of them,
- 44:26I think, but I'll be honest, I'm not going to talk about the PTO aspects of
- 44:30it because I think I might get in trouble from my HR partners if I do that because
- 44:34I'm not sure I understand all the nuances of all of that and how that works.
- 44:39But certainly trying to be there to support the care team is really important.
- 44:42And I think we saw lots of examples of that over the last few weeks.
- 44:46And I know a number of us, for example, pitched in to try to do some shifts
- 44:50in environmental services and some other things when some of our care team members
- 44:54were having a hard time getting to work and trying to make sure that we could
- 44:57still deliver care and do those things and be there to support those care teams.
- 45:01I think we've seen a lot of rounding at all levels of the organization and trying
- 45:05to support those who are particularly anxious about their current circumstance.
- 45:09And then certainly we offer the usual things that we offer all of our care team
- 45:13in terms of, you know, talks base, in terms of AAP and other resources to help
- 45:18support those individuals who are going through an understandably really stress-provoking time.
- 45:23And I know there are some resources that were sent out to the MaineHealth,
- 45:27Maine Medical Center team around this, and we can send a couple of those links
- 45:30out along with the program notes for this program as well.
- 45:34Switching gears, and again, if people want to put questions,
- 45:37we just got one. Let me read this one in the chat about genetic testing.
- 45:42The person is saying it sounds like there should be significant resources to
- 45:46appropriately run this pilot program, so additional genetic counselors,
- 45:50data staff, clinical staff, research staff.
- 45:53How do you envision managing the workforce growth for this pilot and beyond?
- 45:58That's a great point. We have predicted about nine FTEs that will be required
- 46:08for the successful implementation of this program,
- 46:12knowing that we have already a lot of people from our health system that are
- 46:20engaged and are putting time into this project.
- 46:24So that is very helpful.
- 46:28But the nine people that I was mentioning that covers a senior director for
- 46:34the program, a principal investigator, geneticist, genetic counselor, as we talked about.
- 46:41And these are not all full FTEs, but partial FTEs that are going to help with
- 46:47this project. And we are going to phase it over the next 10 years.
- 46:51And we are going to start, as I was mentioning a bit earlier,
- 46:54with a few critical members that are going to be needed to lead the project.
- 47:02So, yeah. We had a couple of questions that are left in email and we are getting
- 47:07short on time, so I want to make sure we run through those.
- 47:09Marissa was actually asking about recommendations that her team had received
- 47:15to have some music in the waiting room with their practice because this would
- 47:18really help with patient satisfaction.
- 47:20Action, but they haven't been able to find a solution to being able to pipe
- 47:23in the music. And they were wondering if there is a system-wide solution to
- 47:27being able to have music in the waiting rooms.
- 47:30Great question. And I don't know of one, but that's something we'll follow up
- 47:33with our IT team on to see if we can get you an answer on that.
- 47:37And so the next one is from Heather.
- 47:40Heather wanted to know, she said, I've noticed that there are many departments
- 47:44that do not have voicemail recordings that clearly state their department or location.
- 47:49Sometimes someone will pick up the phone and they'll just say the department
- 47:53name, but not say the location or what facility they're at.
- 47:57What efforts, if any, are underway to ensure that departments and care teams
- 48:00consistently verbalize both the facility and the department during a patient phone interaction?
- 48:05It's really important, particularly for some of those services that we offer
- 48:08in multiple locations as we try to find the most convenient way to get people
- 48:12or the most timely way to get people scheduled.
- 48:14So I don't know the answer to that per se, but nonetheless, I know there's a
- 48:17lot of work around how do we engage patients when they either call the system
- 48:21or engage us through digital technology.
- 48:24And so I'll follow up to make sure that we're thinking about some sort of scripting
- 48:27or expectations around what that looks like for our patients.
- 48:30There was also another question from another Heather who wanted to know about
- 48:34the approved signatures by MaineHealth.
- 48:37Sometimes you can see that there are like little banners underneath people's
- 48:39signatures representing different groups of people.
- 48:42There is no banner for the American flag. She wants to know why is that and can we do it?
- 48:46I don't know, but I think identifying yourself as an American seems perfectly reasonable to me.
- 48:52So we'll certainly follow up with our team on that as well and see either if
- 48:56there's any reason or maybe we go ahead and encourage that to occur.
- 48:59That's something I certainly could see myself identifying as, for sure.
- 49:03You didn't read my email, Andy. I sent you an email. No, I did not. I apologize.
- 49:07It's been a long, long, long week. Actually, we reached out to Ryan Pauly because
- 49:10we wanted to find out if we could answer this question.
- 49:13And what he mentioned was a lot of these email signature pieces come through
- 49:18the care team member networks, similar to how the Veterans Network has badge reels.
- 49:24And he suggested that Heather reach out to maybe the veteran network,
- 49:30see if there's interest in doing an American flag one, and then they can have
- 49:33a conversation about whether that is something that would be a good way of representing
- 49:37veterans in a signature line, if there's another care team member network that
- 49:41might be helpful to work with her on that.
- 49:44No guarantees, but it is a place to start. And that is where those come from.
- 49:47I like that answer better.
- 49:48Yeah, there you go. We were able to get back to you. Another thing that just
- 49:51popped in the chat, Don McMillan said, talk to me about the music.
- 49:55I'm the person who you should talk to about the music. So we're getting answers right in here.
- 50:01Jodi wanted to know if Trellis Health is going to be participating in the Precision Medicine pilot.
- 50:06I don't know. What's the answer there? We have, I don't know exactly.
- 50:12We have not really talked in detail about that.
- 50:15I'm sorry, but I can get back to you on that.
- 50:19All right. Sounds good. All right. I think we've gotten through the questions.
- 50:24So, and we barely have any time left in the program, and we have so many great recognitions.
- 50:28And Aji, you have so many people to recognize. I love your slides.
- 50:33It's just like name after name. There are so many people involved in the project.
- 50:36So please move forward with your recognition.
- 50:39Thank you so much, Caroline. Well, I first want to thank the executive team
- 50:42that's really prioritizing precision medicine for our health system.
- 50:46I do want also to express my gratitude to Anne Bragia,
- 50:52one of our scientists that's not retired, work at MHIR,
- 50:56and Bob Carlson and the original Precision Medicine Council,
- 51:00who really considered precision medicine as a priority and started their work
- 51:07on this about five years ago.
- 51:09We are standing on the shoulders of giants.
- 51:12Next, I do want to thank the members of the steering committee for our project
- 51:17that are presented here.
- 51:19You recognize many of the faces here.
- 51:21But in particular, I want to thank Cara Granato, Brett Lofredo, Ralph Kamak,
- 51:29Tucker Witter, and Troy Trejo, who have been my partners for the past nine months,
- 51:34spending countless hours with me on this project.
- 51:39And finally, in the next slide, that is where you are going to see the members
- 51:44of the work groups with whom we have been meeting regularly.
- 51:47These are the four work groups that are really the pillars of this project,
- 51:52including the clinical operations work group,
- 51:55the research work group, the education work group, and the data analytics and
- 51:59health information biorepository or repository work group.
- 52:04Without their help and support, we couldn't have done any of the projects that I was talking about.
- 52:10And finally, and importantly, I do want to thank our marketing and communication
- 52:16department that have been very helpful and tremendous partners in the past month
- 52:23to support the definitions and our mission on this.
- 52:27What a team. It takes a big team to do something like this.
- 52:31It's really pretty impactful for us. I mean, this is a big, brilliant endeavor
- 52:34for everyone moving forward.
- 52:37So, Aji, thank you for being with us today, for sure.
- 52:40All right, we've got some recognition this week. And this week marks an exciting
- 52:45and important milestone for MaineHealth and for the Mount Washington Valley community.
- 52:49We're proud to officially recognize the opening of MaineHealth Urgent Care in
- 52:54North Conway. This new center represents our commitment to making sure patients
- 52:58can access the right care in the right place at the right time.
- 53:02Patients in this region now have convenient walk-in access to high-quality,
- 53:06expert urgent care for non-life-threatening illnesses and injuries without the
- 53:10long waits or higher costs often associated with emergency departments.
- 53:15None of this would be possible without an extraordinary amount of teamwork,
- 53:19collaboration, and dedication.
- 53:21From the steering committee to the team at MaineHealth Memorial Hospital,
- 53:25design and construction, the EPIC team, revenue cycle and payer enrollment,
- 53:30MaineHealth Medical Group to the MARCOM team, everyone played an essential role
- 53:34in the successful opening.
- 53:36And finally, a very special thank you to our new MaineHealth Urgent Care team,
- 53:42Ruth Coleman, Sherry Cormier, Abigail Maynard, and Wendy LaRosa,
- 53:46who have been on site preparing, coordinating, and getting ready for this opening.
- 53:51We are so grateful for your energy and dedication.
- 53:56Together, this team effort brings us one step closer to our shared vision of
- 54:01working together so our communities are the healthiest in America.
- 54:04Thank you for the work that you've done to make this possible,
- 54:08and congratulations on the opening of MaineHealth Urgent Care in North Conway.
- 54:14Also got MaineHealth Maine Medical Center pharmacy recognition.
- 54:19I want to recognize the pharmacy team at Maine Health Maine Medical Center, Portland.
- 54:22A couple of weeks ago, Portland's Mayor Mark Dion presented them with a proclamation
- 54:28praising them for their vaccination efforts this fall.
- 54:31The pharmacy team hosted 83 clinics for the city staff, residents,
- 54:34and school communities and administered more than 6,300 vaccines.
- 54:39More than 1,000 of them were in city schools.
- 54:42Congratulations to the team on completing this important public health work.
- 54:48And then on the patient experience front, we have two great patient experience
- 54:52recognitions to tell you about today.
- 54:54The first one is for MaineHealth Waldo Hospital. It says, I cannot say enough
- 55:00about my stay at Waldo Hospital.
- 55:01In the 12 days that I was admitted, hospital staff treated me like an extended family.
- 55:07Doctors brainstormed together to be sure that I had the best treatment program,
- 55:11and nurses worked to make me comfortable and safe.
- 55:14Even the cooks tried to meet my needs with food that I could tolerate.
- 55:18CNAs made me laugh, and even housekeeping was kind. I would recommend the hospital to anyone.
- 55:25Our next recognition is for the team in the neuro-ICU at MaineHealth Maine
- 55:30Medical Center, Portland.
- 55:31A patient wrote, I arrived by ambulance after a brain bleed while skiing.
- 55:37I was worried and scared. Every single person I met, every member of the team
- 55:41treated me as though it was their pleasure to look after me.
- 55:44Thank you for your expertise and your personal attention.
- 55:48A special shout out to all who care for me in the intensive care unit.
- 55:52CNA Torrey Dukes, Dr. Teresa May, nurses Tricia Renfro, and Tracy Valeriotti,
- 55:59and speech language pathologist Jennifer Lobley.
- 56:01I'm so grateful and lucky to have been in your care.
- 56:06Thank you so much. Just two wonderful patient experience stories. Thank you.
- 56:11January was not an easy month, but despite that, you all have done some amazing
- 56:14work, and it's really inspiring to see how well you have really engaged patients
- 56:19during this period of time.
- 56:21Our next open door will be March 25th, and we're going to discuss some operational
- 56:25transformation with Maine Health Chief Operating Officer Kelly Elkins and Chief
- 56:28People Officer Scott Ballard.
- 56:30We look forward to seeing you then. And of course, until then,
- 56:32if you're engaged in patient care, make sure you positively identify the patient
- 56:36first and then wash your hands before treating the patient.
- 56:39We'll see you back here next time. Thank you.